The Biotech Hiring Roadmap

A stage-by-stage guide to proactive talent planning across the drug development lifecycle.

The drug development lifecycle is predictable in its structure. The hiring that supports it should be too.

We’ve outlined a stage-by-stage hiring roadmap – mapping the key roles you need, the window in which recruitment must begin, and the specific risks that accumulate if you leave it too late. Think of it as the timeline your talent strategy should be built around.

Stage 1: Discovery & Target Identification

Hiring Timeline: Now

Discovery is the stage most often treated as a hiring afterthought – teams are small, programmes are speculative, and headcount feels premature. But the scientists you bring in at this stage set the intellectual and operational foundation for everything that follows. Hiring reactively here means critical early science is either delayed or conducted by people who are overextended.

Key roles to hire

• Molecular biologists and biochemists
• Computational chemists and structural biologists
• Medicinal chemists
• Target validation scientists
• Research informatics specialists

The hiring window

These roles should be in place before research programmes begin in earnest. That means recruiting 6–9 months ahead of your planned discovery timeline – accounting for notice periods, onboarding, and the time it takes for a scientist to become genuinely productive in a new environment.

The risk of waiting

Discovery delays rarely announce themselves as talent failures. They present as scientific problems – inconclusive assays, bottlenecked data analysis, slow lead optimisation. In reality, the root cause is often insufficient or misaligned headcount. By the time this is recognised, the programme is already behind.

Stage 2: Preclinical Development

Hiring Timeline: 6–12 months before GLP studies

Preclinical work is where the programme begins to formalise. GLP-compliant studies, toxicology packages, and early formulation work all require specialists who understand not just the science, but the regulatory framework it must meet. These are not roles you can fill in parallel with the work – they must be embedded before the studies begin.

Key roles to hire

• Toxicologists (GLP-compliant)
• DMPK and pharmacokinetics scientists
• Preclinical study directors and monitors
• GLP quality assurance professionals
• Formulation and CMC scientists (early stage)

The hiring window

Start recruitment 6–12 months before GLP study initiation. Senior toxicologists and GLP QA professionals in particular are in short supply and carry long notice periods. Identifying candidates early – even before a role is formally opened – is not premature. It is prudent.

The risk of waiting

A GLP study that begins without the right QA oversight or study directorship is a regulatory liability, not just an operational inconvenience. Deficiencies identified during regulatory review of your preclinical package can trigger requests for repeat studies – at significant cost and delay to your IND or CTA timeline.

Stage 3: Regulatory Filing (IND / CTA)

Hiring Timeline: 12 months before submission

Regulatory filing is the stage that most consistently catches growing biotechs off guard. The IND process in the US and the CTA pathway across EU member states require professionals with highly specific, system-level expertise. These are not roles for generalists learning on the job – and the consequences of under-resourcing them are measured in months of delay.

Key roles to hire

• Regulatory affairs professionals (US and/or EMEA, system-specific)
• CMC regulatory specialists
• Medical writers (IND/CTA experience)
• Clinical pharmacologists
• Regulatory operations and submission managers

The US vs EMEA distinction

In the US, FDA expertise is specialised but navigable within a single regulatory system. In EMEA, the CTA pathway requires country-by-country management – individual national competent authorities and ethics committees, each with their own requirements, timelines, and procedural nuances. EU regulatory professionals with multi-member-state CTA experience represent a genuinely narrow talent pool. Begin identifying candidates 12 months before your planned submission date.

The risk of waiting

Regulatory submissions are not forgiving of last-minute resourcing. A medical writer brought in two months before submission will lack the programme context to write effectively. A regulatory affairs lead hired after the submission strategy has been set may inherit a framework that needs rebuilding. The cost is not just time – it is the compound interest of a delayed clinical start.

Stage 4: Phase I Clinical Trials

Hiring Timeline : 9–12 months before trial start

Phase I marks the first time your compound enters humans – and the first time your organisation needs a genuinely cross-functional clinical team in place. The roles required at this stage span scientific rigour, operational discipline, and regulatory competence simultaneously.

Key roles to hire

• Clinical operations leads and CRAs
• Clinical pharmacologists
• Medical monitors and safety physicians
• Data managers and biostatisticians (early engagement)
• Pharmacovigilance professionals
• Clinical QA specialists

The hiring window

Recruitment should begin 9–12 months before planned trial initiation. Senior medical monitors and clinical operations leads with Phase I experience are in consistent demand – particularly those with experience in your specific therapeutic area. Do not assume availability.

The risk of waiting

Phase I delays are disproportionately expensive relative to trial size. A site activation bottleneck, a safety reporting gap, or a data management deficiency at this stage does not just slow Phase I – it compresses the timeline available for Phase II planning and erodes investor confidence at a critical juncture.

Stage 5: Phase II Clinical Trials

Hiring Timeline: : 9–12 months before trial start

Phase II is where proof-of-concept meets operational scale. Trials become larger, endpoints become more complex, and the regulatory scrutiny intensifies. It is also the stage at which the organisation must begin thinking – seriously – about Phase III, even before Phase II data is in hand.

Key roles to hire

• Senior clinical operations managers
• Biostatisticians and statistical programmers
• Clinical data managers
• Regulatory affairs leads (building toward NDA/MAA planning)
• Medical science liaisons (in therapeutic area)
• Patient recruitment and engagement specialists

Start Phase III planning now

The single most impactful talent decision at Phase II is this: begin identifying Phase III candidates before the data reads out. This is not wasteful – it is the difference between executing on a positive result and spending six months catching up to it. Build the Phase III pipeline as a contingency. If the data supports it, you will be ready to move immediately.

The risk of waiting

Organisations that wait for Phase II results before planning Phase III hiring face a predictable bottleneck: the talent market for senior Phase III clinical operations professionals is highly competitive, and the lead time to fill these roles – at the seniority required – is typically nine to twelve months. A positive Phase II readout with no pipeline means a delay you did not need to incur.

Stage 6: Phase III Clinical Trials

Hiring Timeline: 12+ months before trial start

Phase III is the most consequential, most complex, and most expensive hiring challenge in the DDL. It requires the broadest cross-functional team, generates the data on which approval decisions are made, and leaves almost no margin for talent-related delays. Organisations that begin Phase III hiring less than nine months before programme initiation consistently find themselves competing for the same senior profiles in an already tight market.

Key roles to hire

• VP or Head of Clinical Operations
• Senior clinical project managers and operations directors
• Biostatisticians and statistical programmers (trial-level)
• Regulatory affairs leads (NDA/MAA submission planning)
• Clinical supply chain and IMP logistics specialists
• Safety and pharmacovigilance leads
• Health economics and outcomes research (HEOR) specialists — begin now
• Medical affairs leads

The HEOR signal

The appearance of HEOR professionals on a Phase III hiring list is deliberate and important. Health technology assessment bodies – NICE in the UK, IQWiG in Germany, HAS in France – increasingly expect HEOR evidence to be embedded in trial design, not retrofitted at submission. Hiring HEOR talent at Phase III initiation, rather than at approval, is the difference between market access evidence that is credible and evidence that is scrambled.

The risk of waiting

Phase III delays are the most expensive in drug development – both financially and in terms of competitive position. A trial that starts six months late because the right operations team was not in place does not simply lose six months. It loses the market timing, the patent runway, and potentially the first-mover advantage that justified the investment.

Stage 7: Regulatory Approval (NDA / MAA)

Hiring Timeline: 12–18 months before submission

NDA and MAA submissions are not events – they are the culmination of months of coordinated effort across regulatory affairs, medical writing, CMC, and clinical teams. The professionals responsible for this work need to be embedded in the programme long before the submission window opens, with full context of the data package and the strategic priorities.

Key roles to hire

• Regulatory affairs directors (US and/or EU, submission-experienced)
• Senior medical writers (NDA/MAA experience)
• CMC regulatory leads
• Regulatory operations and eCTD specialists
• Labelling specialists
• Post-approval regulatory affairs professionals (planning ahead)

Begin commercial hiring in parallel

Approval and commercial launch are not sequential hiring events – they are overlapping ones. By the time your NDA or MAA submission is filed, your commercial team should already be in active formation. Waiting for approval before hiring market access and commercial professionals is one of the most common and costly errors in late-stage biotech planning.

The risk of waiting

A submission team assembled at the last minute will be unfamiliar with the programme’s history, the nuances of the data package, and the regulatory strategy that has shaped it. Gaps in institutional knowledge at this stage do not just introduce errors – they reduce the organisation’s ability to respond effectively to agency queries and information requests, which are a near-universal part of the review process.

Stage 8: Commercial Launch (US & EMEA)

Hiring Timeline: 12–24 months before approval

Commercial launch is where the US and EMEA hiring landscapes diverge most sharply – and where the consequences of under-resourcing are most immediately visible. In the US, a successful FDA approval unlocks a single, unified national market. In EMEA, EMA centralised procedure approval is only the beginning: it opens the door to twenty-seven distinct HTA, pricing, and reimbursement processes, each with its own evidence requirements, stakeholder dynamics, and timelines.

Key roles to hire – US

• VP of Commercial and Market Access
• Medical science liaisons (field medical)
• Key account managers
• Managed care and payer access specialists
• Commercial operations and sales force leads

Key roles to hire – EMEA

• Country General Managers (Germany, France, UK, Italy, Spain at minimum)
• Market access and HTA specialists (country-specific: AMNOG, HAS, NICE, AIFA, GENESIS)
• HEOR leads (per market)
• Medical science liaisons (field medical, country-level)
• Pricing and reimbursement professionals
• Government affairs and stakeholder engagement leads

The EMEA reality

EMEA commercial talent – particularly professionals with genuine hands-on experience of national HTA processes – represents one of the most specialised and competitive hiring markets in life sciences. A market access professional who has successfully navigated an AMNOG submission in Germany, built a dossier for the HAS in France, or managed a NICE appraisal in the UK is not interchangeable with their counterparts in other markets. These roles take time to fill with the right candidates and time for those candidates to build the relationships and institutional context that make them effective.

Begin building your commercial pipeline 12–24 months before expected approval. The organisations that launch successfully in Europe are almost universally the ones that started hiring before the approval was confirmed.

The risk of waiting

A delayed commercial launch is not simply a revenue timing issue. In EMEA especially, late market entry compounds across HTA timelines, reimbursement negotiations, and competitive positioning in ways that erode the value of the asset permanently. The cost of hiring too late for launch is not recovered – it is carried.

Stage 9: Post-Market & Life Cycle Management

Hiring Timeline: Build as you launch

Post-approval is not the end of the hiring timeline – it is the beginning of a new one. Phase IV commitments, label extensions, pharmacovigilance obligations, and lifecycle management programmes all require sustained, specialised talent that cannot be resourced on an ad hoc basis.

Key roles to hire

• Pharmacovigilance and drug safety professionals
• Phase IV clinical operations leads
• Regulatory affairs (post-approval variations and line extensions)
• Medical affairs and publication planning leads
• Real-world evidence specialists

Organisations that plan post-approval talent as part of the approval-stage hiring process — rather than treating it as a separate, later problem – maintain operational continuity and avoid the disruption of re-entering the talent market under pressure.

Putting the Roadmap to Work

The nine stages above represent a complete hiring timeline for the drug development lifecycle. Used as a planning tool, they allow any biotech leadership team to answer three questions at any given point in their programme: Which stage are we approaching? What talent do we need in place before we get there? And when does recruitment need to start for that to happen?

The compounding effect of proactive planning is significant. Organisations that hire consistently ahead of their milestones – rather than in response to them – move faster through each stage, experience fewer operational bottlenecks, and make better use of the capital they have raised. Those that hire reactively find that each stage’s delays carry into the next, eroding both timeline and investor confidence over time.

Executing this roadmap effectively requires internal planning discipline and, at key stages, the support of talent partners who understand not just the roles involved, but where they sit in the lifecycle and how competitive the market is at that moment. A specialist life sciences recruitment partner brings more than candidate access – they bring real-time intelligence on talent availability, compensation benchmarks, and market movement that most growing biotechs cannot maintain in-house. At the stages where the talent pool is narrowest and the timeline pressure is greatest – regulatory affairs, senior clinical operations, EMEA market access – that partnership is not a convenience. It is a structural part of executing the plan.

By Dan Bennett, Client Services Director, Skills Alliance